Other Information
−Removed: On July 26, 2023, we entered into an Amendment No.
−Removed: 1 to At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc., H.C.
−Removed: Wainwright & Co.
−Removed: LLC and BTIG, LLC (the “ATM Sales Agreement Amendment”).
−Removed: Pursuant to the ATM Sales Agreement Amendment, BTIG, LLC was added as an Agent for the ATM Offering and the ATM Agreement was amended to provide that the ATM Offering could be conducted off of registration statements on Form S-3 subsequently filed by us.
−Removed: The foregoing description of the ATM Sales Agreement Amendment is qualified in its entirety by reference to the full text of the ATM Sales Agreement Amendment, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
+Added: Not applicable.
Registrant’s
Amended and Restated Certificate of Incorporation.
−Removed: Amended and Restated Bylaws.
+Added: Amended and Restated Bylaws of Viking Therapeutics, Inc., effective as of May 9, 2023.
Form of Common Stock Certificate.
15 unchanged sentences
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline Extensible Business Reporting Language):
−Removed: (i) Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022, (ii) Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022, (iii) Consolidated Statements of Stockholders’
−Removed: Equity (Deficit) for the three and six months ended June 30, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022, and (v) Notes to Consolidated Financial Statements.
+Added: (i) Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022, (ii) Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, (iii) Consolidated Statements of Stockholders’
+Added: Equity (Deficit) for the three and nine months ended September 30, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022, and (v) Notes to Consolidated Financial Statements.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Viking Therapeutics, Inc.
−Removed: July 26, 2023
+Added: October 25, 2023
/s/ Brian Lian, Ph.D.
2 unchanged sentences
(Principal Executive Officer)
−Removed: July 26, 2023
+Added: October 25, 2023
/s/ Greg Zante
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.